Varma Y Sudheer, Kumar Vijay, Biswas Ratnadeep, Ojha Vishnu Shankar, Bhushan Divendu, Kumar Ramesh, Priyadarshi Rajeev Nayan
Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
Department of Emergency Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
J Family Med Prim Care. 2025 Jul;14(7):2987-2996. doi: 10.4103/jfmpc.jfmpc_2032_24. Epub 2025 Jul 21.
This study aimed to evaluate and compare the diagnostic performance of the Platelet/Spleen Length (P/SL) ratio and a novel metric, the Platelet-Albumin/Spleen Length (P*Alb/SL) ratio, in predicting esophageal varices (EVs) among patients with chronic liver disease (CLD).
A cross-sectional study was conducted over a period of 6 months, enrolling 121 newly diagnosed CLD patients without prior treatment for EV or CLD. Data collected, included demographic and clinical details, platelet count, serum albumin, and spleen length via ultrasonography. All patients underwent upper gastrointestinal endoscopy to assess EVs. The P/SL ratio was calculated by dividing platelet count (cells/μL) by spleen length (mm), and the Platelet-Albumin to Spleen Length (P*Alb/SL) ratio by dividing the product of platelet count and serum albumin (g/dL) by spleen length. Diagnostic performance was evaluated using receiver operating characteristic curve analysis and calculating sensitivity and specificity.
The P/SL ratio demonstrated an optimal cutoff of 856 with an area under the curve (AUC) of 0.924 (95% CI: 0.849-0.998), sensitivity of 92%, and specificity of 85.7%. The PAlb/SL ratio had an optimal cutoff of 2194.5, achieving an AUC of 0.928 (95% CI: 0.864-0.992), sensitivity of 81%, and specificity of 95.2%. Both ratios exhibited strong diagnostic performance, with no significant difference between their AUCs ( = 0.712). The diagnostic odds ratios were 69 and 85.26 for the P/SL and PAlb/SL ratios, respectively.
The P/SL ratio proved to be an effective screening tool for EVs in CLD, with high sensitivity for early detection. The PAlb/SL ratio showed similar or slightly superior diagnostic performance, with high specificity and fewer false positives, making it ideal for confirmation. Together, the sequential tandem use of P/SL followed by PAlb/SL provides a practical strategy for risk stratification and patient management, while reducing reliance on the endoscopy and improving resource allocation, especially in resource-limited settings.
本研究旨在评估和比较血小板/脾脏长度(P/SL)比值和一种新指标血小板-白蛋白/脾脏长度(P*Alb/SL)比值在预测慢性肝病(CLD)患者食管静脉曲张(EVs)方面的诊断性能。
进行了一项为期6个月的横断面研究,纳入121例新诊断的未接受过EV或CLD治疗的CLD患者。收集的数据包括人口统计学和临床详细信息、血小板计数、血清白蛋白以及通过超声检查测得的脾脏长度。所有患者均接受上消化道内镜检查以评估EVs。P/SL比值通过将血小板计数(细胞/μL)除以脾脏长度(mm)来计算,血小板-白蛋白与脾脏长度(P*Alb/SL)比值则通过将血小板计数与血清白蛋白(g/dL)的乘积除以脾脏长度来计算。使用受试者工作特征曲线分析并计算敏感性和特异性来评估诊断性能。
P/SL比值显示最佳截断值为856,曲线下面积(AUC)为0.924(95%可信区间:0.849 - 0.998),敏感性为92%,特异性为85.7%。PAlb/SL比值的最佳截断值为2194.5,AUC为0.928(95%可信区间:0.864 - 0.992),敏感性为81%,特异性为95.2%。两种比值均表现出较强的诊断性能,其AUC之间无显著差异(= 0.712)。P/SL和PAlb/SL比值的诊断比值比分别为69和85.26。
P/SL比值被证明是CLD中EVs的一种有效筛查工具,对早期检测具有高敏感性。PAlb/SL比值显示出相似或略优的诊断性能,但具有高特异性和较少的假阳性,使其成为确诊的理想选择。P/SL随后依次使用PAlb/SL的串联使用为风险分层和患者管理提供了一种实用策略,同时减少了对内镜检查的依赖并改善了资源分配,尤其是在资源有限的环境中。